Moreover, non-clinical studies showing that the triplet combination of ET, PAM, and CDK4/6 inhibitors could prevent or delay resistance to single agents in treatment-naïve BC cells [22,26] suggest that this triplet combination would also be effective as first-line therapy [10]. Here, CDK4 is linked to breast cancer.